bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD. The partnership integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles. bioAffinity Technologies, Inc. is a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics.
